GENB · Generate Biomedicines, Inc.
$16.12
+0.13 (+0.81%)
At close · Aug 21
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company's current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$2.07B
Shares
128.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.12
Open$16.10
Day$15.91–16.70
Available close range$11.21–17.41
Avg vol 30d559K
Short int7.3M · 5.7% float · 15.3d
Short vol64%
Last earningsAug 6, 2026
DataFeb 2026–Aug 2026
Filing10-Q · Aug 6
The closing range uses available history since Feb 27, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+9%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
79%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+32%
trailing
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+47% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.67% of float · ▲ +4.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
85 holders — 13F breadth
Squeeze score
79
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+9%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
79%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+47% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.67% of float · ▲ +4.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
85 holders — 13F breadth
Price context
position in its available closing range
Range low $11
Now $16 · 79%
Range high $17
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $457.4M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GENB
this stock
Generate Biomedicines, Inc.
|
$2.07B | — | — | — | 5.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GENB | +3.1% | +20.3% | +32.5% | +15.1% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +4.4% | +16.7% | +20.9% | +12.6% | — |